Interferon-based therapies for hepatitis C: Utilization, costs, and outcomes

American Journal of Pharmacy Benefits

Volumn 5, Issue 1, 2013, Pages 25-33

  Jonk, Yvonne C ^a   Adeniyi, Titilope ^a   Knott, Astrid ^b   Dieperink, Eric W ^b   Ho, Samuel B ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Hepatitis C Resource Center   (United States)

^c Minneapolis VA Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREVALENCE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES;

EID: 84873930264     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244(4902):359-362.
2. World Health Organization, Sixty-Third World Health Assembly. Viral Hepatitis Report by the Secretariat. http://apps.who.int/gb/ebwha/pdf_fi les/WHA63/ A63_15-en.pdf. Published March 25, 2010. Accessed December 17, 2012
3. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006 144(10):705-714.
4. Kim WR, Terrault NA, Pedersen RA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009; 137(5):1680-1686.
5. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90(10):1562-1569.
6. Briggs ME, Baker C, Hall R, et al. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology. 2001;34(6):1200-1205.
7. US Department of Veteran Affairs, Veterans Health Administration, Offi ce of Public Health and Environmental Hazards, Public Health Strategic Health Care Group. The State of Care for Veterans with Chronic Hepatitis C. http://www.hepatitis. va.gov/provider/policy/HCV-state-of-care-2010.asp. Published November 2010. Accessed December 17, 2012.
8. Roselle GA, Danko LH, Kralovic SM, Simbartl LA, Kizer KW. National Hepatitis C Surveillance Day in the Veterans Health Administration of the Department of Veterans Affairs. Mil Med. 2002 167(9):756-759.
9. Dominitz JA, Boyko EJ, Koepsell TD, et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology. 2005; 41(1):88-96.
10. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998 339(21):1485-1492.
11. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomised trial. Lancet. 2001;358(9286):958-965.
12. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-982.
13. McHutchison JG, Everson GT, Gordon SC, et al; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection [published correction appears in N Engl J Med. 2009;361(15):1516]. N Engl J Med. 2009;360(18):1827-1838.
14. McHutchison JG, Manns MP, Muir AJ, et al; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362(14): 1292-1303.
15. Poordad F, McCone J Jr, Bacon BR, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13): 1195-1206.
16. Bacon BR, Gordon SC, Lawitz E, et al; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-1217.
17. Sherman KE, Flamm SL, Afdhal NH, et al; ILLUMINATE Study Team. Responseguided telaprevir combination treatment for hepatitis C virus infection [published correction appears in N Engl J Med. 2011;365(16):1551]. N Engl J Med. 2011; 365(16):1014-1024.
18. National Digestive Diseases Information Clearinghouse (NDDIC). Chronic Hepatitis C: Current Disease Management. Washington, DC: NDDIC; January 2010. Report 10-4230.
19. Department of Veterans Affairs Hepatitis C Resource Center, Yee HS, Currie SL, Darling JM, Wright TL. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program offi ce. Am J Gastroenterol. 2006;101(10):2360-2378.
20. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology. 2002;36(5)(suppl 1):S3-S20.
21. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology. 2007;46(1):37-47.
22. Murphy F, Garthwaite TL. National Hepatitis C Program. Washington, DC: Department of Veterans Affairs; February 27, 2001. VA Directive 2001-009.
23. Kussman MJ. National Hepatitis C Program. Washington, DC: Department of Veterans Affairs; 2007. VA Directive 2007-022
24. Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A costeffectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther. 2003;17(5): 687-694.
25. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003;290(2):228-237.
26. Siebert U, Sroczynski G, Rossol S, et al; German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut. 2003;52(3): 425-432.
27. Sullivan SD, Jensen DM, Bernstein DE, et al. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol. 2004;99(8): 1490-1496.
28. Jamall IS, Yusuf S, Azhar M, Jamall S. Is pegylated interferon superior to interferon, with ribavirin, in chronic hepatitis C genotypes 2/3? World J Gastroenterol. 2008;14(43):6627-6631.
29. Helsper CW, Hellinga HL, van Essen GA, et al. Real-life costs of hepatitis C treatment. Neth J Med. 2012;70(3):145-153.
30. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
31. US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. http://stats.bls.gov/cpi/home.htm. Published 2012. Accessed December 18, 2012.
32. US Department of Veterans Affairs. 2001 National Survey of Veterans (NSV). Final Report. http://www.va.gov/VETDATA/SurveysAndStudies/Final_Report.asp. Published 2001. Accessed December 18, 2012.
33. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341(8): 556-562.
34. Malone DC, Tran TT, Poordad FF. Cost-effi cacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. J Manag Care Pharm. 2005;11(8):687-694.
35. Purdum AG, Johnson KA, Globe DR. Comparing total health care costs and treatment patterns of HIV patients in a managed care setting. AIDS Care. 2004; 16(6):767-780.
36. Favarato D, Hueb W, Gersh BJ, et al; First Year Follow-Up of MASS II Study. Relative cost comparison of treatments for coronary artery disease: the First Year Follow-Up of MASS II study. Circulation. 2003;108(suppl 1):II21-II23.
37. Sales AE. The Veterans Health Administration in the context of health insurance reform. Med Care. 2008;46(10):1020-1022.
38. Families USA Foundation.Getting the Best Price: Lessons Learned from the Medicare Discount Card Program. A Report From Families USA. Report 05-105. http://www.familiesusa.org/resources/publications/reports/getting-the-best-pricesept- 2005.html. Published September 2005. Accessed December 19, 2012.
39. Yeh WS, Armstrong EP, Skrepnek GH, Malone DC. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System. Pharmacotherapy. 2007;27(6):813-824